title: [Primary cardiac lymphoma: cytological diagnosis and treatment with response to polychemotherapy and hematopoietic precursor autotransplant. Presentation of a case a review of the literature].
abstract: The primary cardiac lymphoma (PCL) is an extremely infrequent tumor suffered by immunocompetent patients with a difficult diagnosis and slow progress leading to a serious prognosis and few therapeutically possibilities. It's a primary-cardiac non-Hodgkin's lymphoma (NHL) in a patient of 46-year-old, immunocompetent, who started with a congestive heart failure and atrial flutter. Some examinations were carried out such as a transesophageal echocardiography (TEE), a computed tomography (TC) and a magnetic resonance imaging (MRI) and an intracardiac tumor placed in the interauricular septum was detected. The diagnosis was based on a pleural fluid cytological examination. It was decided to follow a chemotherapy treatment and the autologous peripheral blood stem cells transplantation was carried out. The patient remains in full remission thirty-six months after diagnosis and twenty-nine months after the autotransplant. Our clinical experience indicated that an early and accurate diagnosis combined with the appropriate and aggressive antilymphoma therapy can thus help in obtaining a long survival in patients with PCL.
authors.affiliation: Servicio de Medicina Interna, Hospital Universitari de Girona, Dr. Josep Trueta, C/Av. de França, s/n. 17007-Girona.
authors.forename: C
authors.initials: C
authors.lastname: Porcar Ramells
authors.forename: C
authors.initials: C
authors.lastname: Clemente González
authors.forename: D
authors.initials: D
authors.lastname: García Parés
authors.forename: R
authors.initials: R
authors.lastname: Guardia Sánchez
authors.forename: M J
authors.initials: MJ
authors.lastname: Pérez Ayuso
authors.forename: F
authors.initials: F
authors.lastname: García-Bragado Dalmau
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D001282:Atrial Flutter / Q000209:etiology; D002330:Carmustine / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D017548:Echocardiography, Transesophageal; D005047:Etoposide / Q000008:administration & dosage; D006333:Heart Failure / Q000209:etiology; D006338:Heart Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000628:therapy; D006346:Heart Septum / Q000473:pathology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D006854:Hydrocortisone / Q000008:administration & dosage; D007121:Immunocompetence; D007278:Injections, Spinal; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000628:therapy; D008279:Magnetic Resonance Imaging; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D010996:Pleural Effusion / Q000209:etiology; D011241:Prednisone / Q000008:administration & dosage; D012074:Remission Induction; D014057:Tomography, X-Ray Computed; D019172:Transplantation Conditioning; D014182:Transplantation, Autologous; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine; D011241:Prednisone; D006854:Hydrocortisone; D008727:Methotrexate